Today Biognosys announces the re-launch of its blood proteomics portfolio based on targeted proteomics technology. The existing PlasmaDive™ and PlasmaDeepDive™ Assay Panels will now be offered in 3 sizes for 20, 48 or 96 samples and will come with a license for SpectroDive™ software. In addition, stable isotope labeled standard (SIS) reference peptides needed for absolute quantification of plasma proteins will now be available separately as PlasmaDive™ Reference Peptides and PlasmaDeepDive™ Reference Peptides kits.
Biognosys has developed PlasmaDive™ and PlasmaDeepDive™ for the absolute quantification of human plasma with targeted proteomics. The multiplexed assay panels consist of a complete workflow with sample preparation kit, stable isotope labeled standard (SIS) reference peptides, corresponding assay panel Plug-In and SpectroDive™ – Biognosys proprietary software for the analysis of targeted proteomics data sets acquired with multiple reaction monitoring (MRM) or parallel reaction monitoring (PRM).
With the new offering each component of the panels is now available separately. This allows researchers who already have part of the workflow set up internally to benefit from Biognosys’ solutions in a modular approach.
The new offering for blood proteomics can be found on our online shop here. In case you are interested in our solutions or have any questions please don’t hesitate to contact us at email@example.com.
To learn more about PlasmaDive™ we invite you to join our live webinar on Wednesday, April 26th 2017 at 4.00PM CET (10.00AM EST) titled “Plasma Proteomics in Epidemiology: are we really measuring the correct apolipoproteins for cardiovascular disease risk assessment?” where Prof. Manuel Mayr from King’s College London will show the results of his work on quantifying plasma levels of different apolipoproteins using PlasmaDive and their associations with cardiovascular events over a 10-year observation period. To register for the webinar please use the following link.